在糖尿病视网膜病变中准GLP-1受体激动剂的ER压力
Hanwen Huang1, Ya'nuo Wang1, Shuang Gao1
1Department of Ophthalmology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Er Road, Shanghai 200025, China.
Biochemical pharmacology
|December 11, 2025
概括
类似葡萄糖类-1受体激动剂 (GLP-1RAs) 通过减少内质网膜 (ER) 压力来治疗糖尿病视网膜病变 (DR) 是有前途的. 这些疗法可以保护视网膜细胞免受慢性高血糖和炎症引起的损伤.
科学领域:
- 内分泌学和新陈代谢学
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
背景情况:
- 糖尿病视网膜病变 (DR) 是视力损失的主要原因之一,与内质网膜 (ER) 压力有关.
- 慢性高血糖,氧化压力和炎症在DR中驱动ER压力.
- GLP-1受体激活剂 (GLP-1RAs) 用于2型糖尿病,并显示在DR中的潜力.
研究的目的:
- 审查ER压力和GLP-1RAs在DR中的作用.
- 探索GLP-1RAs如何减轻ER压力驱动的视网膜损伤.
- 突出DR的潜在治疗策略.
主要方法:
- 文献综述,重点关注DR中ER压力机制.
- 对GLP-1RA对视网膜血管和神经功能影响的分析.
- 整合关于ER应激通路 (PERK, IRE1α) 和GLP-1RA作用的证据.
主要成果:
- 慢性高血糖症加剧ER压力,扰乱视网膜氧化还原和平衡.
- 通过调节ER应激通路,GLP-1RAs可能会恢复蛋白质稳定.
- GLP-1RAs显示出在缓解DR患者视网膜功能障碍和亡方面的潜力.
结论:
- 通过准ER压力,GLP-1RAs可能为DR提供一种新的治疗方法.
- 需要进一步的研究来证实机械联系和临床疗效.
- 阐明这些联系对于开发先进的DR疗法至关重要.
相关概念视频
Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
Dipeptidyl Peptidase 4 Inhibitors
557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
G Protein-coupled Receptors
16.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.3K


